Morningstar

Currax Announces ObesityWeek® Data Showing that CONTRAVE® Helps Curb Cravings and Offers Marked Effectiveness in Certain Populations with Obesity

Data to be shared during an ObesityWeek press conference include four of seven presentations supporting CONTRAVE and its utility in helping people lose weight BRENTWOOD, Tenn., Nov. 4, 2025 ...
Benzinga.com

Report: Orexigen Therapeutics Jumped Gun On Contrave Heart Study

Orexigen Therapeutics, Inc. (NASDAQ: OREX) may have jumped the gun in reporting that its anti-obesity drug Contrave offers unexpected benefits to cardiovascular patients. The Miami-based company ...
abc27

Currax Pharmaceuticals LLC to Provide CONTRAVE® at No Cost to Federal Employees During Government Shutdown

Program ensures continued access to treatment for patients enrolled in the Federal Employee & Retirees Health Plan (FEP) BRENTWOOD, Tenn., Oct. 23, 2025 /PRNewswire/ -- Currax Pharmaceuticals LLC, a ...
KXAN

Currax Pharmaceuticals to Spotlight New Research at ObesityWeek® 2025 Highlighting Craving Control, Behavioral Adherence, and Subpopulation Outcomes with CONTRAVE®

Data to be shared during an ObesityWeek press conference includes four of seven data presentations supporting CONTRAVE and its utility in helping people lose weight BRENTWOOD, Tenn., Oct. 28, 2025 ...